SynthesisHepatology international2015
Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis.
Synthesis in Hepatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06085976 (Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.Medicine · 2018Pooled it
- The efficacy and safety of endoscopic ultrasound selective variceal devascularization for the treatment of esophagogastric varices: a retrospective cohort study.BMC gastroenterology · 2026Article
- Impact of preoperative triglyceride levels on hepatic encephalopathy development in TIPS patients: a retrospective cohort study.BMC gastroenterology · 2026Article
- Duration of vasoconstrictors after endoscopic variceal ligation in acute variceal bleeding: A systematic review and network meta-analysis.Hepatology forum · 2026Review
- Choosing Wisely: A Systematic Review of Terlipressin Versus Octreotide for Variceal Bleeding.Cureus · 2025Review
- Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding.Scientific reports · 2024Review
- Efficacy of Endoscopic Intervention plus Growth Inhibitor and Patient Self-Management in the Treatment of Esophagogastric Variceal Bleeding in Cirrhosis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The pharmacodynamic effect of terlipressin versus high-dose octreotide in reducing hepatic venous pressure gradient: a randomized controlled trial.Annals of translational medicine · 2021Article
- Beyond the scope and the glue: update on evaluation and management of gastric varices.BMC gastroenterology · 2020Review
- Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.World journal of gastroenterology · 2020Review
- Somatostatin Analogs in Clinical Practice: a Review.International journal of molecular sciences · 2020Review
- The diagnostic accuracy of routine clinical findings for detection of esophageal varices in rural sub-Saharan Africa where schistosomiasis is endemic.African health sciences · 2019Article
- Update on the management of gastrointestinal varices.World journal of gastrointestinal pharmacology and therapeutics · 2019Review
- Article
- [An evidence-based terlipressin therapy for gastroesophageal variceal hemorrhage].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- No difference in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding and renal functional impairment.European journal of gastroenterology & hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur purpose was to conduct a meta-analysis to compare the effectiveness of vasopressin/terlipressin and somatostatin/octreotide on variceal re-bleeding within and after 5 days of initial control bleeding.
methodsA search was conducted of PubMed, the Cochrane database, and Google Scholar until June 31, 2014 using combinations of the search terms: esophageal varices, variceal re-bleeding, recurrent variceal hemorrhage, early re-bleeding, vasopressin, somatostatin, terlipressin, octreotide. Inclusion criteria were: (1) randomized controlled trials, (2) patients with esophageal or esophageal and gastric varices confirmed by endoscopy, (3) re-bleeding control was evaluated, (4) treatment with somatostatin/vasopressin. Outcome measures were the re-bleeding rates within 5 days (≤ 5 days) or after 5 days (>5 days) after initial treatment.
resultsSix studies were included in the analysis. Five studies had complete data of re-bleeding rate within 5 days after initial treatment, and the combined odds ratio (OR) of 0.87 [95% confidence interval (CI) 0.51, 1.50] indicated that there was no difference in the re-bleeding rate between patients treated with vasopressin/terlipressin or somatostatin/octreotide. Two studies had complete data of the re-bleeding rate 5 days after initial treatment, and the combined OR of 1.12 (95% CI 0.64, 1.95) indicated there was no difference in the re-bleeding rate between patients who were treated with vasopressin/terlipressin or somatostatin/octreotide.
conclusionThere is no difference between vasopressin/terlipressin and somatostatin/octreotide in prevention of re-bleeding after the initial treatment of bleeding esophageal varices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.